Amylyx Pharmaceuticals’ AMX0035 misses primary and secondary endpoints in ALS study
Cambridge, Massachusetts-based Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a key player in the pharmaceutical industry, announced today the top-line results of the PHOENIX study, a critical ... Read More
Alpha Cognition advances Alzheimer’s treatment with new patent filing
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a pioneering biopharmaceutical company in the development of novel treatments for neurodegenerative diseases, has recently taken a significant ... Read More
Olatec Therapeutics set to launch dapansutrile Phase 2 trial in Parkinson’s disease
Olatec Therapeutics, Inc. (Olatec), a leader in the field of selective NLRP3 inhibitors, has embarked on a journey to tackle Parkinson's disease, a neurodegenerative disorder ... Read More
Hemogenyx Pharmaceuticals innovates brain cancer treatment with CBR delivery
Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical group, has made a significant advancement in medical science by demonstrating the ability to deliver its proprietary ... Read More
Zydus Lifesciences to launch Phase 2 Parkinson’s disease trial of ZYIL1
Zydus Lifesciences Limited, a globally recognized pharmaceutical company, has recently obtained the USFDA's approval to commence Phase II clinical study of its NLRP3 inhibitor, ZYIL1, ... Read More
Merck to acquire Caraway Therapeutics in $610m deal for neurodegenerative disease treatments
Merck and Caraway Therapeutics, Inc. have announced a definitive agreement in which Merck, through a subsidiary, will acquire Caraway Therapeutics. The total potential consideration for ... Read More
Amylyx Pharmaceuticals gets RELYVRIO FDA approval for ALS
RELYVRIO FDA approval for ALS : Amylyx Pharmaceuticals has secured approval for RELYVRIO (sodium phenylbutyrate and taurursodiol) from the US Food and Drug Administration (FDA) ... Read More
Arkuda Therapeutics gets $64m booster to advance neurodegenerative treatment
Arkuda Therapeutics, a US-based biotechnology company, has raised $64 million in Series B financing. The new funding will help Arkuda Therapeutics boost the production of ... Read More
Eli Lilly completes $1.04bn acquisition of Prevail Therapeutics to expand gene therapy program
Eli Lilly and Company has officially finalized its acquisition of Prevail Therapeutics in a deal valued at up to $1.04 billion. This acquisition represents a ... Read More
Eli Lilly to acquire Prevail Therapeutics for $1.04bn, expanding gene therapy pipeline
Eli Lilly and Company has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a prominent US gene therapy company specializing in ... Read More